Earnings

Here’s why Abbott Labs stock is getting dinged after a strong earnings beat

Products You May Like

Abbott Chairman of the Board and CEO Robert B. Ford delivers a keynote address at CES 2022 at The Venetian Las Vegas on January 6, 2022 in Las Vegas, Nevada.
Ethan Miller | Getty Images

Abbott Labs delivered a second-quarter earnings beat on Thursday, but the company’s ongoing litigation over its baby formula — plus softer guidance for the current quarter — is dragging down shares. We view the pullback as an opportunity.

Products You May Like

Articles You May Like

Investors should stay with their long-term financial plans no matter who is in the White House, advisors say
Post-Election Analysis: Trump’s Tax Plans and Economic Impact
Mattel pulls thousands of ‘Wicked’ dolls off shelves after printing adult web address on packaging
Liberty Media to spin off assets; CEO Greg Maffei to step down at year-end
The price of bitcoin is soaring. Here’s a key move for investors to reduce future crypto taxes

Leave a Reply

Your email address will not be published. Required fields are marked *